T. Do

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

A. Vangsted, T. Klausen, C. Andersen, 2018, Experimental Hematology & Oncology.

Adverse Drug Events Related to Canagliflozin: A Meta-Analysis of Randomized, Placebo-Controlled Trials

T. Do, S. Muflih, Mohammad S. Shawaqfeh, 2015 .

Impaired circulating myeloid DCs from myeloma patients.

H. Johnsen, I. Svane, T. Do, 2004, Cytotherapy.

Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1–3a follicular lymphoma

M. Bøgsted, K. Dybkær, H. Johnsen, 2018, British journal of haematology.

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

P. Sonneveld, A. Waage, N. Abildgaard, 2018, Haematologica.

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

L. Olsen, I. Svane, T. Klausen, 2020, Frontiers in Immunology.

Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients

A. Vangsted, T. Klausen, C. Andersen, 2018, European journal of haematology.